Investigational drug for multiple system atrophy (parkinsonian type)
Part of Brain & nervous system clinical trials.
This trial tests an experimental drug, ONO-2808, in people with the parkinsonian subtype of multiple system atrophy (MSA-P). It aims to see if the drug can slow disease progression and improve symptoms. Participants must be in the early stages of the disease and able to walk independently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed or likely diagnosis of MSA-P (the parkinsonian type) using current criteria.
- You are in the early stages, meaning symptoms started within the last 5 years.
- You can walk at least 10 steps, turn around, and walk back without help from another person (using a cane or walker is okay).
- You can swallow oral medication and are willing to follow the study schedule.
- You are not pregnant, planning to become pregnant, or breastfeeding.
- If you are on any medications for MSA symptoms, your dose has been stable for at least 60 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
Hear when a new Multiple System Atrophy, Parkinson Variant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.